Clinical bottom line
Pediatric post-COVID-19 multisystem inflammatory syndrome (PIMS), also known as multisystem inflammatory syndrome in children (MIS-C), is a rare but serious hyperinflammatory condition occurring weeks after SARS-CoV-2 infection. Early recognition and outpatient management strategies focusing on timely referral, supportive care, and immunomodulatory therapy initiation are critical to prevent progression to severe organ dysfunction. Current evidence-based guidelines emphasize multidisciplinary evaluation, cardiac monitoring, and individualized immunotherapy, but outpatient management remains challenging due to variable presentations and evolving understanding of pathophysiology (Chang et al., 2024; Emeršič et al., 2023).
What the evidence shows
PIMS/MIS-C typically presents 2–6 weeks following COVID-19 infection with persistent fever, rash, conjunctivitis, gastrointestinal symptoms, and signs of systemic inflammation. The syndrome involves multiple organ systems, notably cardiovascular, gastrointestinal, hematologic, and dermatologic, with potential for rapid deterioration (Botz Bálint et al., 2021; Fortin et al., 2021). Laboratory findings include elevated inflammatory markers (CRP, ferritin), lymphopenia, and elevated cardiac enzymes (Chang et al., 2024).
Recent clinical guidelines recommend initial outpatient evaluation focusing on symptom severity, hemodynamic stability, and laboratory markers to stratify risk and determine the need for hospitalization (Chang et al., 2024). Mild cases without cardiac involvement may be managed with close outpatient monitoring, whereas moderate to severe cases require urgent referral to specialized centers. Immunomodulatory treatments such as intravenous immunoglobulin (IVIG) and corticosteroids are mainstays, with biologics reserved for refractory cases (Emeršič et al., 2023).
Metabolic profiling studies have revealed unique pathophysiological phenotypes in children with PIMS, suggesting distinct immunometabolic pathways that may inform future targeted therapies (unattributed proteomic studies). Cardiac involvement, including myocarditis and coronary artery abnormalities, necessitates echocardiographic assessment and ongoing cardiology follow-up (Botz Bálint et al., 2021).
Caveats and uncertainty
Despite advances, the heterogeneity of clinical presentations and overlap with other pediatric inflammatory conditions complicate diagnosis and management. The optimal timing and choice of immunomodulatory therapy in outpatient settings remain under investigation, with limited high-quality randomized controlled trials to guide practice (Chang et al., 2024). Long-term outcomes, particularly regarding cardiac sequelae, are not fully characterized, warranting cautious prognostication.
Additionally, metabolic phenotype data are preliminary and require validation in larger cohorts before clinical application (unattributed proteomic studies). Variability in access to specialized care and diagnostic resources may limit the applicability of current guidelines in some outpatient settings (Revenco et al., 2020).
How this may change practice
Clinicians should maintain a high index of suspicion for PIMS in children presenting with persistent fever and multisystem symptoms post-COVID-19, even if initial infection was mild or asymptomatic. Early outpatient risk stratification using clinical and laboratory criteria can facilitate timely referral and initiation of immunomodulatory therapy, potentially improving outcomes.
Integration of multidisciplinary teams including pediatrics, infectious diseases, cardiology, and rheumatology is essential for comprehensive care. Awareness of emerging metabolic insights may prompt future biomarker development and personalized treatment approaches. Ongoing education and updates on evolving guidelines will be critical as evidence accumulates.